Post Profile






PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
read more

share

Related Posts


Among Patients Carrying BRCA Mutations, PARP Inhibitor Shows Activity In Pancreatic, Prostate Cancers

Health : Medical News Today

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancr...

PARP inhibitor may be effective against some TNBC lacking BRCA mutations

Health : EurekAlert: Health

(American Association for Cancer Research) The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that di...

MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatic...

Ribociclib Improves Progression-Free Survival for Women with Metastatic Breast Cancer

Health : Newswise Medical News

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of po...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA

Diseases & Conditions / Cancer : EurekAlert: Cancer

(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and...

Comments


Copyright © 2016 Regator, LLC